# Table of Contents

**TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and Atezolizumab** ................................................................................................................................................................................................. 7  
**TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and BCG** ............................................................................................................................................................................................................................................. 7  
**TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and Combination Therapy** ........................................................................................................................................................................................................................................................................................................................................................................... 23  
**TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and Interferon** ................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 24  
**TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and Ipilimumab** ................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 25  
**TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and Nivolumab** ................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 25  
**TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and PD1/PD-L1** ................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 25  
**TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and Pembrolizumab** ................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 26  
**TOPIC: Author Additions** ................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 26

**Note:** This bibliography is organized in topic order and then in alphabetical order by author. The searches were originally conducted on 10/17/16 and then again on 6/17/17 and 7/8/17 to incorporate any additional references.
### Previous Searches

<table>
<thead>
<tr>
<th>Search Terms</th>
<th>Date Limits</th>
<th>Limits</th>
<th>Search Field Tags</th>
<th>EndNote record numbers</th>
<th>Total records found</th>
<th>Total # Duplicates</th>
<th>Resulting # of records in bibliography</th>
<th>Total Drops</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Transitional cell carcinoma OR Bladder cancer OR Urothelial cancer] and BCG vaccine</td>
<td>1995-2016</td>
<td>(&quot;carcinoma, transitional cell&quot;[MeSH Terms] OR &quot;urinary bladder neoplasms&quot;[MeSH Terms]) AND &quot;bcg vaccine&quot;[MeSH Terms] AND (&quot;1995/01/01&quot;[PDAT] : &quot;2016/12/31&quot;[PDAT]) AND &quot;humans&quot;[MeSH Terms] AND (Clinical Trial[ptyp] OR Controlled Clinical Trial[ptyp] OR Randomized Controlled Trial[ptyp] OR Meta-Analysis[ptyp] OR Practice Guideline[ptyp]))</td>
<td>MeSH Terms, Publication Date, Publication Type</td>
<td>10/17/2016</td>
<td>1-229* *Four references were inadvertently deleted and then added back in. The new reference numbers are 321 (formerly record number 85), 322 (formerly record number 32), 323 (formerly record number 22), and 324 (formerly record number 98).</td>
<td>229</td>
<td>0</td>
<td>229</td>
</tr>
<tr>
<td>Search Terms</td>
<td>Date Limits</td>
<td>Limits</td>
<td>Search Field Tags</td>
<td>Data Search Completed</td>
<td>EndNote record numbers</td>
<td>Total records found</td>
<td>Total # Duplicates</td>
<td>Resulting # of records in bibliography</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
<td>--------</td>
<td>------------------</td>
<td>-----------------------</td>
<td>------------------------</td>
<td>-------------------</td>
<td>------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>Author Additions</td>
<td>N/A</td>
<td>Selected publications added by authors</td>
<td>N/A</td>
<td>N/A</td>
<td>283-319</td>
<td>37</td>
<td>1</td>
<td>36</td>
</tr>
<tr>
<td>Error</td>
<td>N/A</td>
<td>One entry was inadvertently added to the database and later dropped</td>
<td>N/A</td>
<td>N/A</td>
<td>320</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Totals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>320</td>
<td>24</td>
<td>296</td>
</tr>
</tbody>
</table>
### Bladder Cancer Immunotherapy Supplemental Literature Searches Conducted June 17, 2017 and July 8, 2017

<table>
<thead>
<tr>
<th>Search Terms</th>
<th>Date Limits</th>
<th>Query Translation</th>
<th>Date Search Completed</th>
<th>Total Refs Identified</th>
<th>Total records found</th>
<th>total # dupes</th>
<th>Total # Irrelevant Records</th>
<th>Resulting # of records in bibliography</th>
<th>New record assignment when imported to original database</th>
<th>Total # Dupes</th>
<th>Resulting # of records in bibliography</th>
</tr>
</thead>
<tbody>
<tr>
<td>transitional cell carcinoma OR bladder cancer OR urothelial cancer AND interferon</td>
<td>1/1/2015-12/31/17</td>
<td>(((&quot;carcinoma, transitional cell&quot;[MeSH Terms] OR &quot;urinary bladder neoplasms&quot;[MeSH Terms]) OR urothelial[All Fields]) AND &quot;neoplasms&quot;[MeSH Terms] AND &quot;interferon&quot;[MeSH Terms] AND (Clinical Trial[ptyp] OR Controlled Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Practice Guideline[ptyp] OR Randomized Controlled Trial[ptyp]) AND ((&quot;2015/01/01&quot;[PDAT] : &quot;2017/12/31&quot;[PDAT]) AND &quot;humans&quot;[MeSH Terms])</td>
<td>6/17/2017</td>
<td>1</td>
<td>24</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>transitional cell carcinoma OR bladder cancer OR urothelial cancer AND ipilimumab</td>
<td>1/1/2015-12/31/17</td>
<td>(((&quot;carcinoma, transitional cell&quot;[MeSH Terms] OR &quot;urinary bladder neoplasms&quot;[MeSH Terms]) OR urothelial[All Fields]) AND &quot;neoplasms&quot;[MeSH Terms] AND &quot;ipilimumab&quot;[Supplementary Concept] AND (Clinical Trial[ptyp] OR Controlled Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Practice Guideline[ptyp] OR Randomized Controlled Trial[ptyp]) AND ((&quot;2015/01/01&quot;[PDAT] : &quot;2017/12/31&quot;[PDAT]) AND &quot;humans&quot;[MeSH Terms])</td>
<td>6/17/2017</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
### Cancer Immunotherapy Guidelines (Bladder): A Bibliography of the Literature In Topic Order

#### Bladder Cancer Immunotherapy Supplemental Literature Searches Conducted June 17, 2017 and July 8, 2017

<table>
<thead>
<tr>
<th>Search Terms</th>
<th>Date Limits</th>
<th>Query Translation</th>
<th>Date Search Completed</th>
<th>Total Refs Identified</th>
<th>Total records found</th>
<th>total # dupes</th>
<th>Total # Irrelevant Records</th>
<th>New record # assignment when imported to original database</th>
<th>Resulting # of records in bibliography</th>
<th>Total # Dupes</th>
<th>Resulting # of records in bibliography</th>
</tr>
</thead>
<tbody>
<tr>
<td>transitional cell carcinoma OR bladder cancer OR urothelial cancer AND durvalumab</td>
<td>1/1/2010-12/31/17</td>
<td>(((&quot;carcinoma, transitional cell&quot;[MeSH Terms] OR &quot;urinary bladder neoplasms&quot;[MeSH Terms]) OR urothelial[All Fields]) AND &quot;neoplasms&quot;[MeSH Terms]) AND &quot;durvalumab&quot;[Supplementary Concept] AND (Clinical Trial[ptyp] OR Controlled Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Practice Guideline[ptyp] OR Randomized Controlled Trial[ptyp]) AND (&quot;2010/01/01&quot;[PDAT] : &quot;2017/12/31&quot;[PDAT]) AND &quot;humans&quot;[MeSH Terms])</td>
<td>6/17/2017</td>
<td>1</td>
<td>34</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>additional references added by Rosenbj1</td>
<td>7/8/2017</td>
<td>(((&quot;carcinoma, transitional cell&quot;[MeSH Terms] OR &quot;urinary bladder neoplasms&quot;[MeSH Terms]) OR urothelial[All Fields]) AND &quot;neoplasms&quot;[MeSH Terms]) AND &quot;avelumab&quot;[Supplementary Concept] AND (Clinical Trial[ptyp] OR Controlled Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Practice Guideline[ptyp] OR Randomized Controlled Trial[ptyp]) AND (&quot;2010/01/01&quot;[PDAT] : &quot;2017/12/31&quot;[PDAT]) AND &quot;humans&quot;[MeSH Terms])</td>
<td>6/17/2017</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>transitional cell carcinoma OR bladder cancer OR urothelial cancer AND avelumab</td>
<td>1/1/2010-12/31/17</td>
<td>(((&quot;carcinoma, transitional cell&quot;[MeSH Terms] OR &quot;urinary bladder neoplasms&quot;[MeSH Terms]) OR urothelial[All Fields]) AND &quot;neoplasms&quot;[MeSH Terms]) AND &quot;avelumab&quot;[Supplementary Concept] AND (Clinical Trial[ptyp] OR Controlled Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Practice Guideline[ptyp] OR Randomized Controlled Trial[ptyp]) AND (&quot;2010/01/01&quot;[PDAT] : &quot;2017/12/31&quot;[PDAT]) AND &quot;humans&quot;[MeSH Terms])</td>
<td>6/17/2017</td>
<td>91</td>
<td>35-125</td>
<td>91</td>
<td>8</td>
<td>82</td>
<td>1</td>
<td>346</td>
<td>0</td>
</tr>
<tr>
<td>transitional cell carcinoma OR bladder cancer OR urothelial cancer AND PDL1/PD-L1</td>
<td>1/1/2010-12/31/17</td>
<td>(((&quot;carcinoma, transitional cell&quot;[MeSH Terms] OR &quot;urinary bladder neoplasms&quot;[MeSH Terms]) OR urothelial[All Fields]) AND &quot;neoplasms&quot;[MeSH Terms]) AND PDL1[All Fields] AND &quot;antigens, cd274&quot;[MeSH Terms] OR (&quot;antigens&quot;[All Fields] AND &quot;cd274&quot;[All Fields]) OR &quot;cd274 antigens&quot;[All Fields] OR (&quot;pd-1&quot;[All Fields] AND &quot;11&quot;[All Fields]) OR &quot;pd 11&quot;[All Fields]) AND (Clinical Trial[ptyp] OR Controlled Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Practice Guideline[ptyp] OR Randomized Controlled Trial[ptyp]) AND (&quot;2010/01/01&quot;[PDAT] : &quot;2017/12/31&quot;[PDAT]) AND &quot;humans&quot;[MeSH Terms])</td>
<td>6/17/2017</td>
<td>91</td>
<td>35-125</td>
<td>91</td>
<td>8</td>
<td>82</td>
<td>1</td>
<td>346</td>
<td>0</td>
</tr>
<tr>
<td>transitional cell carcinoma OR bladder cancer OR urothelial cancer AND peptide derived vaccine</td>
<td>1/1/2010-12/31/17</td>
<td>(((&quot;carcinoma, transitional cell&quot;[MeSH Terms] OR &quot;urinary bladder neoplasms&quot;[MeSH Terms]) OR urothelial[All Fields]) AND &quot;neoplasms&quot;[MeSH Terms]) AND (&quot;vaccines, subunit&quot;[MeSH Terms]) OR (&quot;vaccines&quot;[All Fields] AND &quot;subunit&quot;[All Fields]) OR &quot;subunit vaccines&quot;[All Fields] OR (&quot;peptide&quot;[All Fields] AND &quot;vaccines&quot;[All Fields]) OR (&quot;peptide vaccines&quot;[All Fields]) AND (Clinical Trial[ptyp] OR Controlled Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Practice Guideline[ptyp] OR Randomized Controlled Trial[ptyp]) AND (&quot;2010/01/01&quot;[PDAT] : &quot;2017/12/31&quot;[PDAT]) AND &quot;humans&quot;[MeSH Terms])</td>
<td>6/17/2017</td>
<td>5</td>
<td>254-258</td>
<td>5</td>
<td>1</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**TOTALS** 259 14 35 27

Prepared by Silent Partners, Inc. for SITC • JO21224 • July 11, 2017
TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and Atezolizumab


TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and BCG


139 [113]. Sylvester, R. J., A. P. van der Meijden, et al. (2005). "Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of


**TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and Combination Therapy**


5 [350]. Hemdan, T., R. Johansson, et al. (2014). "5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guerin with


**TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and Interferon**


### TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and Ipilimumab


### TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and Nivolumab


### TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and PD1/PD-L1

**TOPIC: Transitional Cell Carcinoma or Bladder Cancer or Urothelial Cancer and Pembrolizumab**


**TOPIC: Author Additions**


8 [306]. Gore, J. L., M. S. Litwin, et al. (2010). "Use of radical cystectomy for


19 [297]. Lammers, R. J., W. P. Witjes, et al. (2012). "Intracutaneous and


